FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  17 18 19 20 21 22 23 24 25 26 27
 
TXT Vanda Agrees to Pay Over $11 Million in Off-label Suit
09/19/2022
 
 
TXT FDA Reminds on Endotracheal Tube Obstructions
09/16/2022
 
 
TXT HHS Outlines FDA Projects Under Biotech Initiative
09/16/2022
 
 
TXT FDA Challenges Illicit Trade Workshop Attendees
09/15/2022
 
 
TXT Baxter Clearlink Solution Set Recall is Class 1
09/15/2022
 
 
TXT Advisors to Discuss Pulse Oximeter Accuracy
09/15/2022
 
 
TXT Elemental Impurities Guidance
09/15/2022
 
 
TXT Akorn Pays $7.9 Million to Resolve False Claims Suit
09/15/2022
 
 
TXT Top FDA-483, Warning Letter Observations
09/15/2022
 
 
TXT FDA Grants, Denies Catalyst Amifampridine Petition
09/15/2022
 
 
TXT Novartis Wants Restrictions on Entresto ANDAs
09/15/2022
 
 
TXT FDA Rejects Hearing Aid Standardization
09/14/2022
 
 
TXT FDA Partnership on Rare Neurodegenerative Diseases
09/14/2022
 
 
TXT Bob Temple Gets New Title, Role Remains the Same
09/14/2022
 
 
TXT MAPP on SGEs Representing Sponsors Before FDA
09/14/2022
 
 
TXT Affirm Dismissal of Lexapro Case: WLF
09/14/2022
 
 
TXT 3 Observations on Aurobindo FDA-483
09/14/2022
 
 
TXT Texas Longhorn RX Producing Illegal Drugs: FDA
09/13/2022
 
 
TXT $2 Million FDA Grant to Marker Therapeutics
09/13/2022
 
 
TXT Preserve Access to Compounded Hormones: APC
09/13/2022
 
 
TXT ISCT Criticizes Ruling in Cell, Gene Therapy Case
09/13/2022
 
 
TXT FDA Report on Generic Drug Approval Cost Savings
09/13/2022
 
 
TXT FDA in Pistoia Alliance Working Group
09/13/2022
 
 
TXT User Fee Reauthorization Talks Continue
09/13/2022
 
 
TXT FDA Denies Petition on Colonoscopy Preparation
09/12/2022
 
 
TXT FDA Approves BMS Plaque Psoriasis Drug
09/12/2022
 
 
TXT Biomarin Reports Leukemia in Patient on Gene Therapy
09/12/2022
 
 
TXT FDA Taps PATH’s Kaslow as Vaccine Chief
09/09/2022
 
 
TXT Pfizer NDA for Alopecia Drug Accepted for Review
09/09/2022
 
 
TXT Boston Imaging V7 Ultrasound Cleared
09/09/2022
 
 
TXT Nonprescription Drug Label Guidance
09/08/2022
 
 
TXT RWD, RWE Submission Guidance
09/08/2022
 
 
TXT FDA Denies 2014 LASIK Petition
09/08/2022
 
 
TXT UCS Surveying State of Science Under Biden
09/08/2022
 
 
TXT FDA Breast Implant Cancer Alert
09/08/2022
 
 
TXT FDA Emergency Monkeypox Test Guidance
09/08/2022
 
 
TXT Panacea Biotec Inspection is OAI
09/08/2022
 
 
TXT Safety Alert on Abbott’s MitraClip Delivery Systems
09/08/2022
 
 
TXT 7 Observations in Korea’s Hugel FDA-483
09/07/2022
 
 
TXT Pharmacology Pediatric Studies Guidance
09/07/2022
 
 
TXT CDER, CBER Accept 1st ISTAND Submission
09/07/2022
 
 
TXT Stakeholders Want Changes to Supply Chain Guidance
09/07/2022
 
 
TXT Pacira Seeking Expanded Label on Exparel
09/07/2022
 
 
TXT FDA Lifts Hold on Sarepta Duchenne Drug Trial
09/06/2022
 
 
TXT Leaf of Life Marketing Illegal New Drugs: FDA
09/06/2022
 
 
TXT Boston Scientific’s Watchman Gets Revised Label
09/06/2022
 
 
TXT CDER Working to Optimize Drug Absorption
09/06/2022
 
 
TXT FDA Denies Most of Salix Xifaxin Petition
09/06/2022
 
 
TXT Bayer Paying $40 Million to Settle 2 Whistleblower Suits
09/06/2022
 
 
TXT Advancing Regulatory Science at FDA 2022 Report
09/06/2022
 
 
TXT FDA Approves Fresenius Kabi Biosimilar
09/06/2022
 
 
TXT FDA Approves Boehringer Pustular Psoriasis Drug
09/02/2022
 
 
TXT Imfinzi Approved for Biliary Tract Cancer
09/02/2022
 
 
TXT FDA Observations from 3 Biocon Biologics Inspections
09/01/2022
 
 
TXT Cue Health Seeks De Novo for At-Home Flu Test
09/01/2022
 
 
TXT GDUFA Research Supports Generic Drug Development
09/01/2022
 
 
TXT FDA, C-Path Exploring Lysosomal Diseases Group
09/01/2022
 
 
TXT Respironics Troubles Broaden as it Pays $24 Mil. Over False Claims
09/01/2022
 
 
TXT Integra CereLink Monitor Recall is Class 1
09/01/2022
 
 
TXT FDA’s ‘Whole-of-Government’ Approach to Illicit Products
09/01/2022
 
 
TXT Former Pharmatech CEO Gets 37 Months in Jail
09/01/2022
 
 
TXT FDA Refusing to Approve ITCA 650
09/02/2021
 
 
<< Prev  17 18 19 20 21 22 23 24 25 26 27 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving